Eli Lilly & Co is a leading global pharmaceutical company with a particular strength in neuroscience, diabetes and more recently oncology treatments. The group has enjoyed considerable success with anti-depressants such as Cymbalta, and is perhaps best-known for Prozac, a miracle drug which revolutionised the treatment of depression during the 1980s and 1990s. However, it has suffered steep declines in sales of these products as a result of patent expiries. Its current blockbuster roster includes diabetes products Humalog (sales of $2.8bn in 2017), Trulicity ($2.0bn) and Humulin ($1.3bn), as well as Viagra rival Cialis ($2.3bn), cancer drug Alimta ($2.1bn) and Forteo for osteoporosis ($1.7bn). The group has a marketing and development alliance with Boehringer Ingelheim in several countries for diabetes treatments. Unlike many of its main rivals, Lilly has no exposure to OTC consumer healthcare. It currently has a strong position in animal healthcare, where its Lilly Elanco division is the global #2, but it announced plans to spin off this business in 2018. Group revenues for 2017 were $22.9bn, of which almost half came from treatment of diabetes and other endocrinology illnesses. Dave Ricks is chairman & CEO. Lilly is America's oldest surviving drug company, founded in 1876 by Civil War veteran Colonel Eli Lilly. It was a pioneer in the introduction of gelatin-coated pills in late 19th century, and one of the first companies to employ a full-time scientist to develop new compounds. A long-time specialist in diabetes, it was the first company to isolate and then market insulin commercially. Humulin, introduced in 1982, was the first synthetic form of insulin; while Prozac, launched five years later, marked a breakthrough in the treatment of clinical depression.
Which agencies handle advertising for Eli Lilly? Find out more from the Account Assignments database.
Who are the competitors of Eli Lilly? See Pharmaceutical Sector index for other companies
Account assignments & selected contact information
Historical profile information for Eli Lilly
Adbrands Account Assignments track account management for the world's leading brands and companies, including details of which advertising agency handles which accounts in which countries for major markets. Adbrands Weekly Update is a weekly summary of the latest news affecting leading advertisers and their advertising and marketing agencies.
Recent stories from Adbrands Weekly Update:
Adbrands Weekly Update 9th Aug 2018: There was further streamlining in the global pharmaceutical market. Eli Lilly announced plans to spin off its animal health division Elanco as a separate quoted company, most likely before the end of the year. It will retain less than 20% of the business following the IPO. Traditionally a specialist in farm animals, Elanco has strengthened its pet business in recent years with acquisitions including Novartis Animal Health and Boehringer Ingelheim's pet vaccine division. As a result it is now the clear #2 in global animal health with annual sales of around $3bn. But that's still some way behind market leader Zoetis, formerly a division of Pfizer, which had sales of $5.3bn last year.
Adbrands Weekly Update 7th April 2016: Figures from Kantar reveal that US pharmaceutical advertising jumped by 19% in 2015 to $5.4bn, overturning a steady decline over the past decade. That figure matches the previous high, set in 2006. Top spender was AbbVie's Humira with a media outlay estimated at a staggering $357m, a huge year-on-year increase ahead of looming patent expiry. There was a similar last gasp for Pfizer's Lyrica, which loses patent protection in 2018. It spent $328m. Pfizer and BMS's Eliquis came 3rd at $249m ahead of Lilly's Cialis with $222m. Pfizer's Xeljanz rounded out the top five at $183m.
Adbrands Weekly Update 25th Jun 2015: Nielsen released figures for the most advertised pharmaceutical brands of 2014. Combined drug spending soared to $4.5bn, the highest level since the 2008/09 recession, and just the top ten spenders alone accounted for around 40% of that sum, or $1.8bn. Eli Lilly's Cialis toppled last year's leader AbbVie's Humira to take the top spot with spend of almost $249m. Erectile dysfunction rival Viagra, from Pfizer, was the #4 spender at $211m. Pfizer's Lyrica for nerve pain moved up to #2 while Eliquis, a blood thinner joint venture with BMS was #3 at $219m. Humira was still among the top five at $203m. Five other drugs spent between $100m and $200m during the year.
All rights reserved © Mind Advertising Ltd 1998-2018